Requip due to its effects similar to dopamine improves at symptoms of Parkinson’s disease (muscle spasms, stiffness, tremors, etc.).
Active ingredient: Ropinirole
Excipients: hypromellose 2208, hydrogenated castor oil, carmellose sodium, povidone K29-32, maltodextrin, magnesium stearate, lactose monohydrate, colloidal silicon dioxide, mannitol, iron (III) oxide yellow (E172), glyceryl dibehenate.
Shell composition: dye pink Opadry OY-S-24900 (Hypromellose 2910, titanium dioxide (E171), macrogol 400, iron (II) oxide red (E172), iron (III) oxide yellow (E172)).
Requip – antiparkinsonian drug is highly selective dopamine agonist neergolinovy D 2-, D3-receptor, which has peripheral and central action.
Therapeutic of Requip
The nosological classification (ICD-10)
G20 Parkinson’s disease
G21 Secondary parkinsonism
Contraindications of Requip
Severe heart failure, mental disorders in history, liver dysfunction, severe renal impairment (Cl creatinine
Side effects of Requip
From the central and peripheral nervous system: sometimes – psychotic states (including delirium and delusions), perception disorders (including illusions, hallucinations exclusion), increased impulsivity, increased libido including hypersexuality, pathological gambling; very rarely – severe somnolence and episodes of sudden sleep (as in the case of other dopaminergic agents, these symptoms are rarely detected in patients with Parkinson’s disease). By reducing the dose or discontinuation of the drug all the symptoms disappeared. In most cases, used concomitant sedation.
Since the cardiovascular system: often – orthostatic hypotension, decreased blood pressure.
Allergic reactions: very rarely – urticaria, angioedema, rash, pruritus.
Overdose of Requip
Symptoms: when taking more than 24 mg / day – mainly due to dopaminergic activity (such as nausea, dizziness), as well as visual hallucinations, rash, claustrophobia, chorea, palpitations, fatigue, nightmares, vomiting, drowsiness. Also, when taking at least 24 mg / d (or where dose unknown) observed vomiting, cough, fatigue, syncope, including vasovagal, dyskinesia, agitation, chest pain, orthostatic hypotension, drowsiness, confusion.
Treatment: the use of dopamine antagonists such as neuroleptics or metoclopramide, supportive therapy.